 - Progression disease at inclusion, defined by one or more of the following three criteria during androgen deprivation therapy according with the criterion no 3: - PSA progression defined as two elevation of the PSA serum level with 1 week between each measure. Patients who have received an antiandrogen must present disease progression 4 weeks since the last dose of flutamide or 6 weeks since the last dose of bicalutamide or nilutamide. PSA value in screening visit must be 2 μgL 2 ngmL. - Soft tissue progression defined by RECIST 1.1 criteria - Bone lesion progression defined by PCWG2 criteria, with two or more new lesions in a scintigraphy 